Supported by one trial
One controlled phase 3 trial met its main goal. Confirmed needs a second trial or regulatory approval for this use.
Immune reconstitution (cladribine, alemtuzumab, aHSCT): reduce relapses and new lesions in early MS (CIS or RIS)
early MS (CIS or RIS) · Immune reconstitution (cladribine, alemtuzumab, aHSCT)
One controlled phase 3 trial met its main goal. It needs a second trial or regulatory approval to count as confirmed.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 617
Deciding trials (phase 3): 1 met, 0 did not.
Other linked trials: 0
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 3 · 2008 · Placebo-controlled · MSFT-NCT00725985
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-11-02Status changed from Confirmed to Supported by one trial
- 2026-10-27First listed as Confirmed
Related hypotheses
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): prevent attacks in NMOSD
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): reduce relapses and new lesions in relapsing MS
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): reduce relapses and new lesions in relapsing and progressive MS
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): reduce relapses and new lesions in secondary progressive MS
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error